Evidence map›Paper›PMID 35084343›Full record

ArticleJMIR medical informatics2022

Use of Clinical Data Interchange Standards Consortium (CDISC) Standards for Real-world Data: Expert Perspectives From a Qualitative Delphi Survey.

Rhonda Facile, Erin Elizabeth Muhlbradt, Mengchun Gong, Qingna Li, Vaishali Popat, Frank Pétavy, Ronald Cornet, Yaoping Ruan, Daisuke Koide, Toshiki I Saito and 5 more

Abstract read
In one paragraph

Article in JMIR medical informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Recommendations for Standardizing Nuclear Medicine Terminology and Data in the Era of Theranostics and Artificial Intelligence.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rhonda FacileClinical Data Interchange Standards Consortium, Austin, TX, United States.ORCID https://orcid.org/0000-0002-6388-1795
Erin Elizabeth MuhlbradtMedical Science and Computing, a Guidehouse company, Rockville, MD, United States.ORCID https://orcid.org/0000-0002-6823-5864
Mengchun GongDigital Health China Technologies, Bejing, China.ORCID https://orcid.org/0000-0001-8197-6643
Qingna LiInstitute of Clinical Pharmacology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0002-9604-4168
Vaishali PopatFood and Drug Administration, Center for Drug Evaluation Research, Silver Spring, MD, United States.ORCID https://orcid.org/0000-0003-3961-6817
Frank PétavyEuropean Medicines Agency, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0003-3668-9922
Ronald CornetDepartment of Medical Informatics, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers - University of Amsterdam, Amsterdam, Netherlands.ORCID https://orcid.org/0000-0002-1704-5980
Yaoping RuanLinkDoc Technologies, Beijing, China.ORCID https://orcid.org/0000-0002-3929-4195
Daisuke KoideDepartment of Biostatistics & Bioinformatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4238-0334
Toshiki I SaitoNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.ORCID https://orcid.org/0000-0001-5143-9185
Sam HumeClinical Data Interchange Standards Consortium, Austin, TX, United States.ORCID https://orcid.org/0000-0002-6045-7251
Frank RockholdDuke Clinical Research Institute, Duke University Medical Center, Durham, NC, United States.ORCID https://orcid.org/0000-0003-3732-4765
Wenjun BaoJMP Life Sciences, SAS Institute Inc, Cary, NC, United States.ORCID https://orcid.org/0000-0001-8448-1689
Sue DubmanClinical Data Interchange Standards Consortium, Austin, TX, United States.ORCID https://orcid.org/0000-0002-7192-7992
Barbara Jauregui WurstClinical Data Interchange Standards Consortium, Austin, TX, United States.ORCID https://orcid.org/0000-0002-0108-3261

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReal-world data (RWD) and real-world evidence (RWE) are playing increasingly important roles in clinical research and health care decision-making. To leverage RWD and generate reliable RWE, data should be well defined and structured in a way that is semantically interoperable and consistent across stakeholders. The adoption of data standards is one of the cornerstones supporting high-quality evidence for the development of clinical medicine and therapeutics. Clinical Data Interchange Standards Consortium (CDISC) data standards are mature, globally recognized, and heavily used by the pharmaceutical industry for regulatory submissions. The CDISC RWD Connect Initiative aims to better understand the barriers to implementing CDISC standards for RWD and to identify the tools and guidance needed to more easily implement them.

objectiveThe aim of this study is to understand the barriers to implementing CDISC standards for RWD and to identify the tools and guidance that may be needed to implement CDISC standards more easily for this purpose.

methodsWe conducted a qualitative Delphi survey involving an expert advisory board with multiple key stakeholders, with 3 rounds of input and review.

resultsOverall, 66 experts participated in round 1, 56 in round 2, and 49 in round 3 of the Delphi survey. Their inputs were collected and analyzed, culminating in group statements. It was widely agreed that the standardization of RWD is highly necessary, and the primary focus should be on its ability to improve data sharing and the quality of RWE. The priorities for RWD standardization included electronic health records, such as data shared using Health Level 7 Fast Health care Interoperability Resources (FHIR), and the data stemming from observational studies. With different standardization efforts already underway in these areas, a gap analysis should be performed to identify the areas where synergies and efficiencies are possible and then collaborate with stakeholders to create or extend existing mappings between CDISC and other standards, controlled terminologies, and models to represent data originating across different sources.

conclusionsThere are many ongoing data standardization efforts around human health data-related activities, each with different definitions, levels of granularity, and purpose. Among these, CDISC has been successful in standardizing clinical trial-based data for regulation worldwide. However, the complexity of the CDISC standards and the fact that they were developed for different purposes, combined with the lack of awareness and incentives to use a new standard and insufficient training and implementation support, are significant barriers to setting up the use of CDISC standards for RWD. The collection and dissemination of use cases, development of tools and support systems for the RWD community, and collaboration with other standards development organizations are potential steps forward. Using CDISC will help link clinical trial data and RWD and promote innovation in health data science.

Indexed as

academic researchclinical data standardsclinical trialsdata integrationDelphi surveyelectronic health recordsFAIR principlesobservational datapublic health datareal-world datareal-world evidenceregistry dataregulatory submission

Identifiers

PMID35084343
PMCPMC8832264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.